Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Mitralign

Mitralign?uq=PEM9b6PF
2003 FOUNDED
PRIVATE STATUS
41-50 EMPLOYEES
Series F LATEST DEAL TYPE
$9.8M LATEST DEAL AMOUNT
16 INVESTORS
Description

Developer of catheter-based mitral valve repair system. The company has developed direct transcatheter annuloplasty system designed to treat both functional mitral regurgitation and tricuspid regurgitation.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Surgical Devices
Primary Office
  • 3 Highwood Drive
  • Suite 200 East
  • Tewksbury, MA 01876
  • United States

+1 (978) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Mitralign’s full profile, request a free trial.

Mitralign Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series F) 02-Feb-2018 $9.8M 00000 00000 Completed Profitable
10. Later Stage VC (Series E) 16-May-2016 000.00 00000 000.00 Completed Profitable
9. Debt - General 22-Apr-2016 00.000 000.00 Completed Profitable
8. Later Stage VC (Series E) 19-Jun-2014 00.000 000.00 000.00 Completed Profitable
7. Later Stage VC 26-Oct-2012 00.00 000.00 Completed Profitable
6. Debt - General 11-Sep-2012 000 000.00 Completed Profitable
5. Later Stage VC (Series D) 16-May-2012 0000 000.00 0000 Completed Profitable
4. Debt - General 01-Jul-2010 000.00 Completed Profitable
3. Later Stage VC (Series C) 10-Dec-2007 $24.1M $42.5M 000.00 Completed Profitable
2. Early Stage VC (Series B) 21-Apr-2006 $13.3M $18.3M 000.00 Completed Profitable
To view this company’s complete deal history including valuation and funding, request access »

Mitralign Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series F 00,000,000 00.00 00.00 00 00.00 000
Junior Convertible 000,000 00.000000 00 0000 0000 00 0000 00
Series E 0,000,000 00.000000 00.00 000.00 000.00 00 000.00 0.000
Series D2 000,000 00.000000 000.0 0000 0000 00 000.00 0.000
Series D1 000,000 00.000000 00.0 0000 0000 00 000.00 0.000
Series C 000,000 00.000000 0000 0000 00 0000.00 0.000
Series B 000,000 00.000000 0000 0000 00 000.00 0.000
Series A2 47,619 $0.001000 $105 $105 1x $91.72 0.13%
Series A1 13,152 $0.001000 $105 $105 1x $91.72 0.04%
To view this company’s complete Cap Table, request access »

Mitralign Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Delong Capital Venture Capital Minority 000 0000 000000 0
Xeraya Capital Venture Capital Minority 000 0000 000000 0
DiNova Venture Capital Venture Capital Minority 000 0000 000000 0
Qiming Venture Partners Venture Capital Minority 000 0000 000000 0
Saints Capital Secondary Buyer Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Mitralign Executive Team (15)

Name Title Board
Seat
Contact
Info
Lisa Wipperman-Heine Chief Operating Officer
Steven Cahalane Chief Technology Officer
Richard Geoffrion Co-Founder, Chief Executive Officer, President & Board Member
Sara Vidmar Vice President, Clinical & Regulatory Affairs
Lisa Mastromattei Vice President, Finance & Administration

6 Former Executives

You’re viewing 5 of 15 executives. Get the full list »

Mitralign Board Members (11)

Name Representing Role Since Contact
Info
Aditya Puri Xeraya Capital Board Member 000 0000
Carrie Bates Triathlon Medical Ventures Board Member 000 0000
Daniel Cole Oxford Bioscience Partners Board Member 000 0000
Daniel Lemaitre Self Board Member 000 0000
Martien van Osch Forbion Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 11 board members. Get the full list »